TickerGuard
Buy Day today: Poor (42) Weak market breadth · no major macro event
AVBP

ArriVent BioPharma, Inc.

Healthcare · Biotechnology

10.50$ -6.6% vs. previous close Closing price · As of: Nov 20, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of ArriVent BioPharma, Inc. (AVBP). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — AVBP
Segment Q3 2026
Life science NQG5.0M 100.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: November 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?